Downloads

31. Predesigned MGB Probe Assays For Gene Expression Analysis 10/21/2026

    Hydrolysis probes built on minor groove binder chemistry pair shorter sequences with low background, offering gene-specific quantification across protein-coding genes without the assay development.

32. Scaling ADC Manufacturing Without Compromising Quality 10/21/2026

    Moving ADC manufacturing to commercial scale alters mixing, solvent distribution, and more. Controlling these scale-dependent effects determines whether quality attributes and process performance hold.

33. From Laboratory To Launchpad: Japan's Cell And Gene Therapy Ecosystem Hits Its Stride 10/21/2026

    Japan is emerging as a credible cell and gene therapy hub as regulation, manufacturing, and capital advance, despite gaps in funding, talent, risk culture, and language.

34. Flexible Deployment For Any Digital Ecosystem 10/21/2026

    Deployment choices for a biopharma data platform range from cloud-hosted SaaS to full on-premises control, with managed setup, maintenance, and upgrades that reduce the internal IT burden.

35. Predict Smarter. De-Risk Earlier. 10/21/2026

    Developability liabilities that surface late leave little room to re-engineer. Standardized assay data and complete datasets support earlier risk detection, more reliable AI predictions, and more.

36. Reducing Plastic While Strengthening Brands And Industrial Performance 10/21/2026

    Replacing plastic with recyclable carton alternatives raises a design and execution question: how packaging, machinery, inspection, and qualification work together without costing premium brand appeal.

37. Is Your Supply Chain Ready For The End Of Class VI? 10/21/2026

    Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.

38. Advancing Drug Product Manufacturing With A Risk-Based Approach 10/20/2026

    Single-use systems are now standard, yet expectations for their use keep shifting. Integrity assurance across the lifecycle underpins a contamination control strategy that can withstand review.

39. GMP-Ready Mammalian Cell Line Development Platform 10/20/2026

    Optimizing vector, host, and process together can shorten the path from stable pool to GMP while keeping titers and quality consistent across 50L to 2,000L scales.

40. Linking Biomarkers To Clinical Proof-Of-Mechanism 10/19/2026

    Proving CNS delivery and target engagement in neurodegenerative therapies requires aligned clinical pharmacology and bioanalysis, from model selection to validated assays.